(Q34004622)

English

Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

Pneumocystis carinii

object named as

Pneumocystis carinii

1 reference

based on heuristic

inferred from title

author name string

Chung JB

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Armstrong K

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Schwartz JS

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Albert D

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 August 2000

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

43

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1841-1848

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Wegener Granulomatosis: An Analysis of 158 Patients

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia. Review of 53 cases

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

The cost-effectiveness of preventing AIDS-related opportunistic infections

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Successful Chemoprophylaxis forPneumocystis cariniiPneumonitis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii Pneumonia Among Patients Without AIDS at a Cancer Hospital

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

PNEUMOCYSTIS CARINII PNEUMONIA IN A FAMILY.

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Progressive pulmonary infiltrates in a patient with polymyositis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii Pneumonia: A Cluster of Eleven Cases

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Wegener's granulomatosis: Patient-reported effects of disease on health, function, and income

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii infection

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Infectious complications of cyclophosphamide treatment for vasculitis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Opportunistic infections in patients with temporal arteritis treated with corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Intensity of immunosuppressive therapy and the incidence of pneumocystis carinii pneumonitis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Fatal pneumocystis pneumonia in an adult. Report of a case

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystic carinii pneumonia in the adult. Report of a primary case

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii Pneumonia in Patients with Connective Tissue Disease

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis and Mucormycosis Pneumonitis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia treated with pyrimethamine and sulfadiazine

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

The compromised host and infection. I. Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Has the incidence of Pneumocystis carinii pneumonia in cancer patients increased with the AIDS epidemic?

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Should inpatients with Pneumocystis carinii be isolated?

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Possible transfer of Pneumocystis carinii between kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Possible transfer of Pneumocystis carinii between immunodeficient patients

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Five-Year Absence of Pneumocystis carinii Pneumonitis in a Pediatric Oncology Center

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200008%2943%3A8%3C1841%3A%3AAID-ANR21%3E3.0.CO%3B2-Q

21 January 2018

Identifiers

10.1002/1529-0131(200008)43:8<1841::AID-ANR21>3.0.CO;2-Q

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34004622&oldid=1879223832"